CN114072427B - 抗dll3嵌合抗原受体及其用途 - Google Patents

抗dll3嵌合抗原受体及其用途 Download PDF

Info

Publication number
CN114072427B
CN114072427B CN202080047990.8A CN202080047990A CN114072427B CN 114072427 B CN114072427 B CN 114072427B CN 202080047990 A CN202080047990 A CN 202080047990A CN 114072427 B CN114072427 B CN 114072427B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
dll3
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080047990.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114072427A (zh
Inventor
赵涛
彭园园
唐安
王素娟
杨帅
张望
武术
郝瑞栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Priority to CN202311129421.XA priority Critical patent/CN117106099A/zh
Priority to CN202410399472.2A priority patent/CN118420777A/zh
Priority to CN202410399887.XA priority patent/CN118496374A/zh
Publication of CN114072427A publication Critical patent/CN114072427A/zh
Application granted granted Critical
Publication of CN114072427B publication Critical patent/CN114072427B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080047990.8A 2019-07-17 2020-07-17 抗dll3嵌合抗原受体及其用途 Active CN114072427B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202311129421.XA CN117106099A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399472.2A CN118420777A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399887.XA CN118496374A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019096360 2019-07-17
CNPCT/CN2019/096360 2019-07-17
CN2020090587 2020-05-15
CNPCT/CN2020/090587 2020-05-15
PCT/CN2020/102717 WO2021008610A1 (en) 2019-07-17 2020-07-17 Anti-dll3 chimeric antigen receptors and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202311129421.XA Division CN117106099A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399887.XA Division CN118496374A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399472.2A Division CN118420777A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途

Publications (2)

Publication Number Publication Date
CN114072427A CN114072427A (zh) 2022-02-18
CN114072427B true CN114072427B (zh) 2024-04-26

Family

ID=74210175

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202080047990.8A Active CN114072427B (zh) 2019-07-17 2020-07-17 抗dll3嵌合抗原受体及其用途
CN202311129421.XA Pending CN117106099A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399887.XA Pending CN118496374A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399472.2A Pending CN118420777A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202311129421.XA Pending CN117106099A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399887.XA Pending CN118496374A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途
CN202410399472.2A Pending CN118420777A (zh) 2019-07-17 2020-07-17 一种抗dll3嵌合抗原受体及其用途

Country Status (9)

Country Link
US (2) US12421292B2 (https=)
EP (2) EP4527466A3 (https=)
JP (3) JP7748933B2 (https=)
KR (1) KR20220035367A (https=)
CN (4) CN114072427B (https=)
AU (1) AU2020314509A1 (https=)
CA (1) CA3146019A1 (https=)
TW (2) TW202535924A (https=)
WO (1) WO2021008610A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298223A (zh) 2020-03-12 2022-11-04 南京传奇生物科技有限公司 磷脂酰肌醇蛋白聚糖-2结合部分、嵌合抗原受体及其用途
EP4313081A4 (en) * 2021-04-02 2025-04-09 Nanjing Legend Biotech Co., Ltd. MANIPULATED IMMUNE CELLS AND THEIR USES
AU2022339815A1 (en) * 2021-09-02 2024-03-14 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting dll3 and uses thereof
AU2023297866A1 (en) * 2022-06-28 2024-12-12 Resolution Therapeutics Limited Switch receptors and modified immune cells
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Ｄｌｌ３抗原結合構築物
WO2024044779A2 (en) * 2022-08-26 2024-02-29 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
CN115820698B (zh) * 2022-11-22 2025-01-21 浙江康佰裕生物科技有限公司 含有嵌合抗原受体和嵌合转换开关受体编码基因的融合基因及其应用
CN116004547B (zh) * 2023-03-06 2025-04-25 浙江康佰裕生物科技有限公司 一种辐照car-t细胞及其制备方法与应用
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
AU2024347905A1 (en) * 2023-09-26 2026-04-02 Legend Biotech Ireland Limited Dll3 binding moieties and uses thereof
WO2025201493A1 (zh) * 2024-03-29 2025-10-02 诺纳生物（苏州）有限公司 Dll3结合分子及其用途
WO2025212519A1 (en) * 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
WO2025240849A1 (en) * 2024-05-16 2025-11-20 The Brigham And Women's Hospital, Inc. Trem2 chimeric antigen receptors and uses thereof
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
CN119708238B (zh) * 2025-02-27 2025-07-04 昕传生物科技(北京)有限公司 靶向dll3的抗体、嵌合抗原受体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105153315A (zh) * 2015-10-09 2015-12-16 重庆倍思益生物科技有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
WO2016138038A1 (en) * 2015-02-23 2016-09-01 Stemcentrx, Inc. Anti-dll3 chimeric antigen receptors and methods of use
WO2018044866A1 (en) * 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
CN108276493A (zh) * 2016-12-30 2018-07-13 南京传奇生物科技有限公司 一种新型嵌合抗原受体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CN110536700A (zh) 2017-04-19 2019-12-03 南加利福尼亚大学 用于治疗癌症的组合物和方法
WO2019067805A1 (en) * 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
EP3774921A4 (en) 2018-04-03 2022-01-05 Dragonfly Therapeutics, Inc. ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT
JP7479290B2 (ja) * 2018-04-10 2024-05-08 アムジエン・インコーポレーテツド Ｄｌｌ３に対するキメラ受容体及びその使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138038A1 (en) * 2015-02-23 2016-09-01 Stemcentrx, Inc. Anti-dll3 chimeric antigen receptors and methods of use
CN105153315A (zh) * 2015-10-09 2015-12-16 重庆倍思益生物科技有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
WO2018044866A1 (en) * 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
CN108276493A (zh) * 2016-12-30 2018-07-13 南京传奇生物科技有限公司 一种新型嵌合抗原受体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DLL3: an emerging target in small cell lung cancer;OWEN，D.H. et al.;Journal of Hematology & Oncology;第12卷;摘要，图1 *
OWEN，D.H. et al..DLL3: an emerging target in small cell lung cancer.Journal of Hematology & Oncology.2019,第12卷摘要，图1. *

Also Published As

Publication number Publication date
WO2021008610A1 (en) 2021-01-21
EP3999550A1 (en) 2022-05-25
JP2026001061A (ja) 2026-01-06
CN118496374A (zh) 2024-08-16
EP4527466A3 (en) 2025-06-18
TW202116812A (zh) 2021-05-01
JP2025069305A (ja) 2025-04-30
US20260078166A1 (en) 2026-03-19
EP3999550A4 (en) 2023-09-06
US12421292B2 (en) 2025-09-23
TW202535924A (zh) 2025-09-16
CN117106099A (zh) 2023-11-24
CA3146019A1 (en) 2021-01-21
US20220249563A1 (en) 2022-08-11
JP7748933B2 (ja) 2025-10-03
JP2022542543A (ja) 2022-10-05
CN118420777A (zh) 2024-08-02
EP4527466A2 (en) 2025-03-26
AU2020314509A1 (en) 2022-01-06
KR20220035367A (ko) 2022-03-22
CN114072427A (zh) 2022-02-18
TWI883026B (zh) 2025-05-11

Similar Documents

Publication Publication Date Title
CN114072427B (zh) 抗dll3嵌合抗原受体及其用途
CN112639102A (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
AU2020287373A1 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
CN113195542A (zh) Cd30-结合部分、嵌合抗原受体及其用途
JP2018522564A (ja) 抗グリピカン３抗体およびその使用
WO2017159287A1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
JP2015527070A5 (https=)
CN111727057A (zh) 与lag3和pd1结合的治疗分子
US20250000976A1 (en) Anti-bcma single domain antibodies and therapeutic constructs
CN113891718A (zh) 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞
WO2015172341A1 (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
WO2024037628A1 (zh) 一种双特异性抗体及其应用
US20230265185A1 (en) Anti-cd22 single domain antibodies and therapeutic constructs
HK40110214A (zh) 一种抗dll3嵌合抗原受体及其用途
HK40110781A (zh) 一种抗dll3嵌合抗原受体及其用途
HK40098926A (zh) 一种抗dll3嵌合抗原受体及其用途
HK40065826A (zh) 抗dll3嵌合抗原受体及其用途
HK40065826B (zh) 抗dll3嵌合抗原受体及其用途
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
EP4141028A1 (en) Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
KR20260016889A (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
CN120137042A (zh) 一种抗st2单克隆抗体与应用
WO2025133609A1 (en) Polypeptide binding glypican-3
CN118931846A (zh) 一种分泌融合蛋白的细胞及其应用
HK40041676A (en) Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065826

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant